Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pilar Mendoza

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Journal of Experimental Medicine|July 28, 2019
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoirChristian Gaebler, Julio C C Lorenzi, Thiago Y Oliveira, et al.
Nature Medicine|February 5, 2020
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunityJulia Niessl, Amy E Baxter, Pilar Mendoza, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2018
Relationship between intact HIV-1 proviruses in circulating CD4<sup>+</sup> T cells and rebound viruses emerging during treatment interruptionChing-Lan Lu, Joy A Pai, Lilian Nogueira, et al.
Journal of Virology|December 10, 2020
Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African IsolatesJulio C C Lorenzi, Pilar Mendoza, Yehuda Z Cohen, et al.
Molecular Cancer|February 5, 2022
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemiaAlejandro M Hortal, Clara L Oeste, Claudia Cifuentes, et al.
Science Signaling|May 31, 2018
R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processesPilar Mendoza, Nuria Martínez-Martín, Elena R Bovolenta, et al.
The Journal of Experimental Medicine|July 22, 2020
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesFabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesFabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
The Journal of Experimental Medicine|August 4, 2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Yehuda Z Cohen, Julio C C Lorenzi, Lisa Krassnig, et al.
NPJ Vaccines|July 6, 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccineChaitanya Kurhade, Wei Chen, Weiqiang Li, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Journal of Experimental Medicine|July 28, 2019
Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoirChristian Gaebler, Julio C C Lorenzi, Thiago Y Oliveira, et al.
Nature Medicine|February 5, 2020
Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunityJulia Niessl, Amy E Baxter, Pilar Mendoza, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2018
Relationship between intact HIV-1 proviruses in circulating CD4<sup>+</sup> T cells and rebound viruses emerging during treatment interruptionChing-Lan Lu, Joy A Pai, Lilian Nogueira, et al.
Journal of Virology|December 10, 2020
Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African IsolatesJulio C C Lorenzi, Pilar Mendoza, Yehuda Z Cohen, et al.
Molecular Cancer|February 5, 2022
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemiaAlejandro M Hortal, Clara L Oeste, Claudia Cifuentes, et al.
Science Signaling|May 31, 2018
R-Ras2 is required for germinal center formation to aid B cells during energetically demanding processesPilar Mendoza, Nuria Martínez-Martín, Elena R Bovolenta, et al.
The Journal of Experimental Medicine|July 22, 2020
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesFabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2020
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesFabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
The Journal of Experimental Medicine|August 4, 2018
Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117Yehuda Z Cohen, Julio C C Lorenzi, Lisa Krassnig, et al.
NPJ Vaccines|July 6, 2026
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccineChaitanya Kurhade, Wei Chen, Weiqiang Li, et al.
Pageof 3